In the present study, LWGA-SA coacervates encapsulating EGF were evaluated for in vitro activity in keratinocytes, in vivo wound healing efficacy in streptozotocin-induced diabetic mice, and storage stability, to evaluate their potential as a novel therapeutic modality for diabetic foot ulcers. This evidence concerns the gene EGF and diabetic foot.